quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:00:00·24d
PRRelease
Beta Bionics Inc. logo

Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care

BBNX· Beta Bionics Inc.
Health Care
Original source

Companies

  • BBNX
    Beta Bionics Inc.
    Health Care

Recent analyst ratings

  • Feb 9UpdateUBS$24.00
  • Jan 27UpdateTD Cowen$17.00
  • Jan 9UpdateBofA Securities-
  • Oct 21UpdateStifel$26.00
  • Oct 1UpdateGoldman$26.00
  • Jun 16UpdateTruist$26.00

Related

  • SEC2d
    SEC Form 10-Q filed by Beta Bionics Inc.
  • SEC2d
    Beta Bionics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR2d
    Beta Bionics Announces First Quarter 2026 Financial Results and Raises Full Year 2026 Guidance
  • SEC13d
    SEC Form DEFA14A filed by Beta Bionics Inc.
  • SEC13d
    SEC Form DEF 14A filed by Beta Bionics Inc.
  • PR24d
    Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.
  • INSIDER38d
    Chief Medical Officer Russell Steven Jon sold $30,069 worth of shares (1,025 units at $29.34), decreasing direct ownership by 0.57% to 178,071 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022